M R Gilbert

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Management of patients with low-grade gliomas
    Mark R Gilbert
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Neurol Clin 25:1073-88, ix. 2007
  2. pmc Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD, Anderson Cancer Center Houston, TX, USA
    Ther Clin Risk Manag 3:1027-33. 2007
  3. doi request reprint Primary brain tumors, delta 24 and tumor metabolism. Interview by Rona Williamson
    Mark R Gilbert
    Anderson Cancer Center, Houston, TX, USA
    Expert Rev Neurother 13:353-5. 2013
  4. doi request reprint On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 15:24-6. 2013
  5. ncbi request reprint Brain metastases: still an 'orphan' disease?
    M R Gilbert
    Department of Clinical Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0100, Houston, TX 77030, USA
    Curr Oncol Rep 3:463-6. 2001
  6. ncbi request reprint Designing clinical trials for brain tumors: the next generation
    Mark R Gilbert
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 9:49-54. 2007
  7. ncbi request reprint Advances in the treatment of primary brain tumors: dawn of a new era?
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 8:45-9. 2006
  8. doi request reprint Ependymomas in adults
    Mark R Gilbert
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77025, USA
    Curr Neurol Neurosci Rep 10:240-7. 2010
  9. doi request reprint Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
    Mark R Gilbert
    Department of Neuro Oncology, M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 106:147-53. 2012
  10. ncbi request reprint Neoplastic meningitis: a unique disease process or a 'test tube' for evaluating cancer treatments?
    Mark R Gilbert
    Department of Clinical Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0100, Houston, TX 77030, USA
    Curr Oncol Rep 5:11-4. 2003

Research Grants

  1. NABTC - M.D. Anderson Clinical Center
    Mark Gilbert; Fiscal Year: 2007

Detail Information

Publications74

  1. ncbi request reprint Management of patients with low-grade gliomas
    Mark R Gilbert
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Neurol Clin 25:1073-88, ix. 2007
    ..Recent advances in molecular characterization, imaging, and treatment of these tumors underscore this current focus of investigations...
  2. pmc Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD, Anderson Cancer Center Houston, TX, USA
    Ther Clin Risk Manag 3:1027-33. 2007
    ..Studies are also underway to develop molecular markers, such as expression of MGMT that may help select the patients most likely to benefit from this treatment...
  3. doi request reprint Primary brain tumors, delta 24 and tumor metabolism. Interview by Rona Williamson
    Mark R Gilbert
    Anderson Cancer Center, Houston, TX, USA
    Expert Rev Neurother 13:353-5. 2013
    ..His research focus has been in the area of clinical and translational research for primary brain tumors. This includes novel clinical trial designs and the integration of correlative tumor biology with these clinical studies...
  4. doi request reprint On the pathway to success: defining subtypes of gliomas for better treatment selection and refining the meaning of success
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 15:24-6. 2013
    ....
  5. ncbi request reprint Brain metastases: still an 'orphan' disease?
    M R Gilbert
    Department of Clinical Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0100, Houston, TX 77030, USA
    Curr Oncol Rep 3:463-6. 2001
    ....
  6. ncbi request reprint Designing clinical trials for brain tumors: the next generation
    Mark R Gilbert
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 9:49-54. 2007
    ..Finally, investigators have increased interest in determining the impact of treatment on other measures, such as symptom burden, functional status, and quality of life as survival has improved...
  7. ncbi request reprint Advances in the treatment of primary brain tumors: dawn of a new era?
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 8:45-9. 2006
    ....
  8. doi request reprint Ependymomas in adults
    Mark R Gilbert
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77025, USA
    Curr Neurol Neurosci Rep 10:240-7. 2010
    ..Ongoing laboratory studies have uncovered important signal transduction pathways that may be better therapeutic targets, leading to the development of clinical trials using targeted agents...
  9. doi request reprint Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery
    Mark R Gilbert
    Department of Neuro Oncology, M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 106:147-53. 2012
    ..However, these results demonstrating drug delivery to tumor do support continued investigation of this agent as preliminary results from recent studies combining cilengitide with cytotoxic therapies are promising...
  10. ncbi request reprint Neoplastic meningitis: a unique disease process or a 'test tube' for evaluating cancer treatments?
    Mark R Gilbert
    Department of Clinical Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0100, Houston, TX 77030, USA
    Curr Oncol Rep 5:11-4. 2003
    ....
  11. pmc A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Unit 431, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 12:1167-72. 2010
    ..Multiple cytostatic agents can be safely combined with dose-dense temozolomide. The factorial-based phase II portion of this study is currently ongoing...
  12. pmc Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme
    M D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Br J Cancer 101:615-20. 2009
    ....
  13. ncbi request reprint Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
    T S Armstrong
    The University of Texas Health Science Center at Houston, School of Nursing, Houston, Texas 77030, USA
    J Neurooncol 80:27-35. 2006
    ..Primary brain tumor (PBT) patients are unique in the occurrence of neurologic symptoms. Currently, no instrument exists that measures both neurologic and cancer-related symptoms...
  14. ncbi request reprint Molecularly targeted therapies for malignant gliomas: advances and challenges
    Marta Penas-Prado
    The UT MD Anderson Cancer Center, Department of Neuro Oncology, Houston, 77030 TX, USA
    Expert Rev Anticancer Ther 7:641-61. 2007
    ..Third, we need to optimize the design of preclinical and clinical trials to obtain the maximum amount of information in the shortest period of time...
  15. ncbi request reprint Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status
    Morris D Groves
    Department of Neuro Oncology, Unit 431, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 80:83-90. 2006
    ....
  16. ncbi request reprint A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe, 431, Houston, TX, 77030, USA
    J Neurooncol 81:271-7. 2007
    ..Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)...
  17. ncbi request reprint Diffusely infiltrative low-grade gliomas in adults
    Frederick F Lang
    Department of Neurosurgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1236-45. 2006
    ..This article reviews the most recent data regarding the treatment of LGG, emphasizing evidenced based approaches from current clinical trials...
  18. pmc A multigene predictor of outcome in glioblastoma
    Howard Colman
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77401, USA
    Neuro Oncol 12:49-57. 2010
    ..The profile has potential clinical application both for optimization of therapy in GBM and for the identification of novel therapies targeting tumors refractory to standard therapy...
  19. ncbi request reprint Net clinical benefit: functional endpoints in brain tumor clinical trials
    Terri S Armstrong
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030, USA
    Curr Oncol Rep 9:60-5. 2007
    ..This paper reviews these three approaches and discusses their potential use in evaluation of therapies for patients with primary brain tumors...
  20. ncbi request reprint Imaging techniques in neuro-oncology
    Terri S Armstrong
    University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Semin Oncol Nurs 20:231-9. 2004
    ..To review neuroimaging techniques used in the diagnosis and follow-up of patients with brain tumors as well as promising new technology...
  21. pmc Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  22. pmc A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
    ..IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered...
  23. pmc Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neuro Oncol 13:324-33. 2011
    ..EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity...
  24. doi request reprint Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
    Morris D Groves
    Departments of Neuro Oncology, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:229-34. 2009
    ..We chose to measure these molecules in the cerebrospinal fluid (CSF) of melanoma, breast, and lung cancer patients being evaluated for neoplastic meningitis (NM)...
  25. pmc Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
    W K Alfred Yung
    Department of Neuro Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Neuro Oncol 12:1061-70. 2010
    ..EGFR amplification was not associated with erlotinib activity. Given the large CIs and nonrandomized nature of the study, results should be interpreted cautiously...
  26. doi request reprint Long-term anti-inflammatory and antihistamine medication use and adult glioma risk
    Michael E Scheurer
    Department of Epidemiology, University of Texas MD Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Cancer Epidemiol Biomarkers Prev 17:1277-81. 2008
    ..Our results lend additional support for an important but unknown link between malignant brain tumors and immune mediators...
  27. pmc Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study
    Vinay K Puduvalli
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston TX 77030, USA
    J Clin Oncol 22:4282-9. 2004
    ..Fenretinide induces apoptosis in malignant gliomas in vitro. This two-stage phase II trial was conducted to determine the efficacy of fenretinide in adults with recurrent malignant gliomas...
  28. ncbi request reprint Glial tumors--new approaches in chemotherapy
    Terri S Armstrong
    M D Anderson Cancer Center, Houston, TX
    J Neurosci Nurs 34:326-30. 2002
    ..Agents designed to target specific processes and structures involved in tumor cell division and innovative combinations of cytotoxic and cytostatic therapies offer future hope for the efficacious treatment of gliomas...
  29. ncbi request reprint Seize the moment to learn about epilepsy in people with cancer
    Terri S Armstrong
    Clin J Oncol Nurs 7:163-9. 2003
    ..Oncology nurses must be aware of the potential seriousness of this complication and implement appropriate strategies to assist patients in maintaining safety and quality of life...
  30. ncbi request reprint Chemotherapy-induced peripheral neuropathy
    Terri Armstrong
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncol Nurs Forum 32:305-11. 2005
    ..To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy...
  31. ncbi request reprint Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
    ..Carboplatin plus erlotinib is well tolerated but has modest activity in unselected patients. Future trials should be stratified based on optimal molecular or clinical characteristics...
  32. pmc Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma
    Michael E Scheurer
    Department of Epidemiology, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:6640-6. 2008
    ..Malignant gliomas are the most common type of primary brain tumor in adults, however, few prognostic factors have been identified...
  33. pmc Genetic variants in inflammation pathway genes and asthma in glioma susceptibility
    E Amirian
    Departments of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Neuro Oncol 12:444-52. 2010
    ..0001). Our study indicates that polymorphisms in inflammation genes are associated with glioma susceptibility, especially when a history of asthma/allergies is absent...
  34. ncbi request reprint New molecular targets in malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Neurol 20:712-8. 2007
    ..The purpose of this review is to provide an update on the identification of novel molecular targets in neurooncology and their translation into clinical practice...
  35. pmc Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience
    Terri S Armstrong
    Department of Integrative Nursing Care, Room 791, 6901 Bertner Ave, Houston, TX 77030, USA
    Neuro Oncol 12:862-70. 2010
    ..Reclassification of ependymoma by neuropathologists is common. Results of this study have lead to a multicenter study to further define important diagnostic and prognostic variables for adults with ependymoma...
  36. ncbi request reprint The treatment of neoplastic meningitis
    Terri S Armstrong
    The University of Texas, Department of Neuro Oncology, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Opin Pharmacother 5:1929-35. 2004
    ..Therefore, careful evaluation and treatment planning is warranted in order to avoid treatment-associated toxicities and to maximise the impact of the treatment on the disease process...
  37. ncbi request reprint The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors
    J Matthew McDonald
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 104:1468-77. 2005
    ..The authors sought to determine whether histology was an equivalent or superior predictor of outcome compared with 1p/19q status in 131 patients with AO tumors...
  38. pmc MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
    Andreana L Rivera
    Departments of Pathology and Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0097, Houston, TX 77030, USA
    Neuro Oncol 12:116-21. 2010
    ..Since this biomarker has also been shown to predict response to alkylating agents, perhaps MGMT promoter methylation represents a general, favorable prognostic factor in GBM...
  39. pmc Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies
    Frederick F Lang
    Department of Neurosurgery, The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77005 4009, USA
    Neuro Oncol 4:268-77. 2002
    ..Specifically, the authors recommend brain-applicable phase I and II clinical trial strategies that take advantage of the targeted nature of new agents to maximize information about their efficacy, toxicity, and molecular effects...
  40. doi request reprint Mood disturbance in glioma patients
    A A Acquaye
    Department of Neuro Oncology, MDACC, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 113:505-12. 2013
    ..The use of concomitant medications, demographic factors, recurrence and income are associated with mood disturbance and interventions may need to be tailored to these underlying factors...
  41. pmc A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy
    Mark R Gilbert
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Neuro Oncol 4:261-7. 2002
    ..Temozolomide was safe and effective in treating newly diagnosed GBM and AA before radiotherapy. This pre-irradiation treatment approach appears promising, but will require additional evaluation in comparative studies...
  42. doi request reprint The role of chemotherapy in the treatment of patients with brain metastases from solid tumors
    Tobias Walbert
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Int J Clin Oncol 14:299-306. 2009
    ..Future treatment advances will require a multidisciplinary approach integrating surgical, radiation, and chemotherapeutic options to improve neurological function and quality of life, rather than just focusing on survival endpoints...
  43. ncbi request reprint Treatment of astrocytomas
    Javier Gonzalez
    MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Curr Opin Neurol 18:632-8. 2005
    ..We will review recent developments in the understanding of the biology of these neoplasms and recent trials demonstrating promising improvements in the survival of patients with malignant gliomas...
  44. ncbi request reprint Seizure risk in brain tumor patients with conversion to generic levetiracetam
    Terri S Armstrong
    University of Texas Health Science Center, Houston School of Nursing, 6901 Bertner Ave, Houston, TX 77030, USA
    J Neurooncol 98:137-41. 2010
    ..The final patient required an increased dose of levetiracetam. As has been described with generic substitution of other anticonvulsants, patients switched to generic levetiracetam may be at risk for breakthrough seizure activity...
  45. ncbi request reprint Central nervous system toxicity from cancer treatment
    Terri Armstrong
    Department of Neuro Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 6:11-9. 2004
    ..Prompt recognition of these problems and their causes will have an impact on patient care in all areas of oncology...
  46. pmc Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients
    Lindsay Kilburn
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
    Cancer 116:2242-9. 2010
    ..The current study was performed to investigate the role of GST enzyme polymorphisms in predicting the survival of patients with AG...
  47. pmc Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk
    Yanhong Liu
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 31:1762-9. 2010
    ..However, polymorphisms in DNA strand break repair genes that may determine mutagen sensitivity are not well studied in cancer risk, especially in gliomas...
  48. ncbi request reprint Cerebral radiation necrosis
    Pierre Giglio
    University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Neurologist 9:180-8. 2003
    ..This is important in achieving one of the most important goals of cancer care-maintaining quality of life...
  49. doi request reprint Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module
    Terri S Armstrong
    Department of Integrative Care, School of Nursing, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    J Neurosurg Spine 12:421-30. 2010
    ..The objective of this study was to develop a reliable and valid self-reporting instrument for patients with spine tumors...
  50. ncbi request reprint Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation
    Luo Wang
    Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:1627-32. 2006
    ..We investigated whether hTERT MNS16A variant genotype predicted survival in GBM patients...
  51. doi request reprint Clinical utility of the MDASI-BT in patients with brain metastases
    Terri S Armstrong
    Department of Integrative Nursing Care, The University of Texas Health Science Center School of Nursing, Houston, Texas 77030, USA
    J Pain Symptom Manage 37:331-40. 2009
    ..The MDASI-BT demonstrated validity and reliability in brain metastases patients and can be used to identify and monitor symptom occurrence in relation to treatment course and survival...
  52. ncbi request reprint Risk factors for fatigue severity in primary brain tumor patients
    Terri S Armstrong
    Department of Integrative Nursing Care, School of Nursing, University of Texas Health Science Center, Houston, Texas 77030, USA
    Cancer 116:2707-15. 2010
    ..Other factors have not been explored. The aim of this study was to identify demographic and clinical factors that predict fatigue severity and to evaluate the association of fatigue with other symptoms throughout the disease trajectory...
  53. ncbi request reprint Use of complementary and alternative medical therapy by patients with primary brain tumors
    Terri S Armstrong
    Department of Integrative Nursing Care, University of Texas Health Science Center School of Nursing, 6901 Bertner Avenue, Houston, TX 77030, USA
    Curr Neurol Neurosci Rep 8:264-8. 2008
    ..Further studies are needed to evaluate the impact of CAM on symptom control or tumor growth in this vulnerable patient population...
  54. ncbi request reprint Advances in molecular therapies in patients with brain tumors
    Ivo W Tremont-Lukats
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Control 10:125-37. 2003
    ..An area under intense investigation is the use of small molecules targeting intracellular signaling pathways that interfere with growth, invasion, and metastasis of high-grade gliomas...
  55. ncbi request reprint Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma
    Mark R Gilbert
    Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Clin Cancer Res 9:2940-9. 2003
    ....
  56. pmc Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study
    Surasak Phuphanich
    The New Approaches to Brain Tumor Therapy CNS Consortium, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Neuro Oncol 7:177-82. 2005
    ..The pharmacology of PB appears to be affected by concomitant administration of P450-inducing anticonvulsants...
  57. ncbi request reprint Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms
    Arnab Chakravarti
    Department of Radiation Oncology, Massachusetts General Hospital Harvard Medical School, Boston, 02114, USA
    Clin Cancer Res 12:4738-46. 2006
    ..In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells...
  58. ncbi request reprint Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study
    Timothy F Cloughesy
    UCLA Neuro Oncology Program, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA 90095, USA
    J Clin Oncol 24:3651-6. 2006
    ..Because tipifarnib undergoes extensive hepatic metabolism, MTD is doubled in patients on EIAEDs. The population included 67 patients with glioblastoma multiforme (GBM) and an exploratory group of 22 patients with anaplastic glioma (AG)...
  59. ncbi request reprint Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
    Andrew B Lassman
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 11:7841-50. 2005
    ....
  60. ncbi request reprint New treatments for malignant gliomas: careful evaluation and cautious optimism required
    Mark R Gilbert
    Ann Intern Med 144:371-3. 2006
  61. ncbi request reprint Chemoradiotherapy in malignant glioma: standard of care and future directions
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    J Clin Oncol 25:4127-36. 2007
    ....
  62. ncbi request reprint Anaplastic astrocytoma: diagnosis, prognosis, and management
    Siew Ju See
    Department of Neurology, National Neuroscience Institute, Singapore General Hospital, Singapore
    Semin Oncol 31:618-34. 2004
    ..Ongoing clinical research investigations are also summarized, reflecting advances in our knowledge of the molecular pathogenesis of these tumors and providing hope for significant improvements in patient outcomes...
  63. doi request reprint Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
    Monika E Hegi
    Laboratory of Tumor Biology and Genetics, Department of Neurosurgery BH 19 110, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland
    J Clin Oncol 26:4189-99. 2008
    ..Herein we review the data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas and describe ongoing studies that are testing resistance-modulating strategies...
  64. pmc Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study
    John J Laterra
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Neuro Oncol 6:15-20. 2004
    ..However, overall survival is not significantly improved when compared with the New Approaches to Brain Tumor Therapy GBM database or other comparable patient populations...
  65. pmc Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
    Kathleen R Lamborn
    Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, UC Clinics 808, San Francisco, CA 94143 0372, USA
    Neuro Oncol 10:162-70. 2008
    ..Earlier assessments of progression status also predicted survival and may be incorporated in the design of future clinical trials...
  66. pmc Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11
    Tracy T Batchelor
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:21-7. 2004
    ..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations...
  67. ncbi request reprint Central nervous system cancers
    Steven S Brem
    H Lee Moffitt Cancer Center and Research Institute
    J Natl Compr Canc Netw 6:456-504. 2008
  68. ncbi request reprint Neurologic complications of non-Hodgkin's lymphoma
    Pierre Giglio
    Department of Neurological Sciences, University of Nebraska Medical Center, 982045 Nebraska Medical Center, Omaha, NE 68198 2045, USA
    Curr Oncol Rep 7:61-5. 2005
    ..This review discusses direct involvement of the peripheral nervous system by lymphoma and paraneoplastic disease and briefly addresses some nervous system infections in lymphoma patients...
  69. ncbi request reprint Anaplastic oligodendroglial tumors: a tale of two trials
    Mark R Gilbert
    J Clin Oncol 24:2689-90. 2006
  70. pmc Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium
    Susan M Chang
    Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0350, USA
    Neuro Oncol 10:631-42. 2008
    ..It would also include a combined phase 0/I pharmacokinetic study to determine the safety and biologically optimal dose of the agent and to verify successful modulation of the target prior to initiating a larger, phase II efficacy study...
  71. ncbi request reprint Response of glioblastomas to EGFR kinase inhibitors
    Andrew B Lassman
    N Engl J Med 354:525-6; author reply 525-6. 2006
  72. ncbi request reprint ANNA-2: an antibody associated with paraneoplastic opsoclonus in a patient with large-cell carcinoma of the lung with neuroendocrine features--correlation of clinical improvement with tumor response
    Rodrigo Erlich
    Department of Oncology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224, USA
    Cancer Invest 22:257-61. 2004
    ..The patient had an unexpectedly dramatic resolution of the neurologic dysfunction after receiving antineoplastic treatment. Symptom improvement paralleled a progressive decline of serum ANNA-2 antibody titers to undetectable levels...
  73. ncbi request reprint Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma
    Meena K Tanwar
    Department of Surgery Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:4364-8. 2002
    ..YKL-40 serum levels were substantially elevated in many of the GBM patients. Statistical analysis of these data indicates that in patients with glioma, serum YKL-40 levels correlate with tumor grade and potentially tumor burden in GBM...
  74. ncbi request reprint Chemotherapy in adults with gliomas
    Siew Ju See
    Department of Neurology, National Neuroscience Institute Singapore General Hospital campus, Outram Road, Singapore 169608
    Ann Acad Med Singapore 36:364-6. 2007
    ..This review article summarises the recent developments and approaches in the use of chemotherapy to treat adult patients with astrocytomas and oligodendrogliomas...

Research Grants2

  1. NABTC - M.D. Anderson Clinical Center
    Mark Gilbert; Fiscal Year: 2007
    ..The NABTC continues with the long-term goal of developing more effective treatments for patients with primary brain tumors, particularly malignant gliomas, combining longevity with the quality of survival. ..